Cerebrolysin in SAH (Subarachnoidal Haemorrhage) - Observational Study

Subarachnoid haemorrhage often affects people in middle age and is associated with high mortality or neurological damage. In recent years, advances in surgical techniques have im-proved the mortality rate. However, there is still need for the research for the optimal possible final effect of treatment. In our study, we've decided to examine the effect of a multimodal approach including Cerebrolysin in the supportive treatment of patients. We've examined the supply of neuroprotective drugs and neuromonitoring.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

SAH (Subarachnoid Hemorrhage) Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Hemorrhage Intracranial Hemorrhages Nervous System Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Subarachnoid Hemorrhage Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Pomeranian Medical University, University Hospital no.1

Szczecin, Poland

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

age >18 years old, diagnosis of SAH, treatment in ICU conditions

Exclusion criteria

age <18 years, medical history of allergy to Cerebrolysin, acute renal failure, pregnancy, multi organ trauma, death within 48 hours after admission

Treatment and study plan

Primary outcomes

GOS Glasgow Outcome Scale

Time frame: 1 month

Glasgow Outcome Scale - 5 points scale, characterizing the patients' deficits

Secondary outcomes

LOS Length of Stay

Time frame: hospitalisation time

length of stay in days, that patient spent in hospital/ intensive care unit
mortality

Time frame: 1 month

mortality

Sponsors and collaborators

Lead sponsor

Pomeranian Medical University Szczecin

Other

Registry information

Official study title

Cerebrolysin in Patients Diagnosed With SAH - an Observational Cohort Study (PILOT)

Important dates

Study start: 2021
Primary completion: 2022
Study completion: 2023
First posted: May 28, 2024
Registry last updated: May 28, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed